| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.39 M USD | -6.14 M USD | 3.97 M USD | 6.50 M USD | -1.68 M USD | 2.90 M USD | 1.86 M USD | -1.23 M USD | -2.84 M USD | -6.45 M USD | -9.63 M USD | -3.43 M USD |
| Depreciation & Amortization | 1.60 M USD | 1.70 M USD | 2.10 M USD | 1.50 M USD | 1.20 M USD | 825000 USD | 606000 USD | 360000 USD | 168000 USD | 156000 USD | 214000 USD | 213000 USD |
| Stock-Based Compensation | 654000 USD | 1.12 M USD | 864000 USD | 912000 USD | 598000 USD | 600000 USD | 636000 USD | 1.00 M USD | 2.66 M USD | 2.60 M USD | 3.16 M USD | 2.81 M USD |
| Capital Expenditures | 389000 USD | 836000 USD | 2.87 M USD | 2.38 M USD | 3.28 M USD | 2.22 M USD | 834000 USD | 1.23 M USD | 766000 USD | 322000 USD | 119000 USD | 234000 USD |
| Cash Flow from Investing | -389000 USD | -836000 USD | -2.87 M USD | -2.38 M USD | -3.17 M USD | -2.22 M USD | -834000 USD | -1.23 M USD | -766000 USD | -322000 USD | -114000 USD | -234000 USD |
| Cash Flow from Financing | 170000 USD | -527000 USD | 11000 USD | 207000 USD | 1.20 M USD | 4.42 M USD | 1.20 M USD | 13000 USD | 4.32 M USD | 2000 USD | 13.21 M USD | 21000 USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | 0 USD | 634000 USD | 74000 USD | 0 USD | — | — | — | — | — | — | — | — |
| Free Cash Flow | 7.00 M USD | -6.97 M USD | 1.10 M USD | 4.11 M USD | -4.96 M USD | 685000 USD | 1.03 M USD | -2.46 M USD | -3.61 M USD | -6.77 M USD | -9.75 M USD | -3.67 M USD |
Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology. The primary function of Champions Oncology is to provide personalized solutions that support pharmaceutical companies and research institutions in understanding the complex biology of cancer. This is achieved through their pioneering ex vivo and in vivo platforms, primarily the TumorGraft Technology, which enables the testing of cancer therapies on live patient-derived tumor cells in a controlled environment. Champions Oncology plays a critical role in the pharmaceutical industry by offering predictive insights that can accelerate the development pipeline and potential success of oncology drugs. This service is crucial for researchers targeting various cancer types as they seek to understand treatment responses and develop targeted therapies. The company's offerings have significant implications in advancing precision medicine and optimizing clinical trial design, making it a valued partner for innovative cancer research initiatives globally.